Literature DB >> 30192166

Meropenem/colistin versus meropenem/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia.

Hossein Khalili1, Lida Shojaei2, Mostafa Mohammadi3, Mohammad-Taghi Beigmohammadi3, Alireza Abdollahi4, Mahsa Doomanlou5.   

Abstract

AIM: Efficacy of colistin and ampicillin-sulbactam have not been compared in treatment of ventilator-associated pneumonia due to A. baumannii. Efficacy of colistin and ampicillin-sulbactam in combination with meropenem were compared in treatment of ventilator-associated pneumonia due to carbapenem-resistant A. baumannii.
METHOD: 47 patients with ventilator-associated pneumonia due to carbapenem-resistant A. baumannii were randomized to receive meropenem/colistin or meropenem/ampicillin-sulbactam for 14 days. Clinical and microbiological responses and 28-day mortality were considered as outcomes.
RESULTS: Clinical response (75 vs 69.6%; p = 0.75) and microbial eradication (87.50 vs 91.3%; p = 0.59) were comparable between meropenem/colistin and meropenem/ampicillin-sulbactam groups, respectively.
CONCLUSION: In this study, clinical and microbiological response were comparable between the meropenem/colistin and meropenem/ampicillin-sulbactam groups.

Entities:  

Keywords:  Acinetobacter; ampicillin–sulbactam; colistin; pneumonia

Mesh：

Substances：

Year:  2018        PMID： 30192166     DOI： 10.2217/cer-2018-0037

Source DB:  PubMed          Journal:  J Comp Eff Res        ISSN： 2042-6305            Impact factor:   1.744


  5 in total

1.  Reply to Epling and Powers, "Cefiderocol and the Need for Higher-Quality Evidence: Methods Matter for Patients".

Authors:  Marco Falcone; Giusy Tiseo
Journal:  Antimicrob Agents Chemother       Date:  2022-07-18       Impact factor: 5.938

2.  Antimicrobial stewardship program (ASP): an effective implementing technique for the therapy efficiency of meropenem and vancomycin antibiotics in Iranian pediatric patients.

Authors:  Aliakbar Rahbarimanesh; Sayed Yousef Mojtahedi; Payman Sadeghi; Maryam Ghodsi; Sara Kianfar; Leila Khedmat; Saeedreza Jamali Moghadam Siyahkali; Mohammad Kaji Yazdi; Anahita Izadi
Journal:  Ann Clin Microbiol Antimicrob       Date:  2019-01-29       Impact factor: 3.944

3.  Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis.

Authors:  Cheng Lyu; Yuyi Zhang; Xiaofen Liu; Jufang Wu; Jing Zhang
Journal:  BMC Infect Dis       Date:  2020-04-21       Impact factor: 3.090

Review 4.  Infectious disease: how to manage Gram-positive and Gram-negative pathogen conundrums with dual beta-lactam therapy.

Authors:  Alireza FakhriRavari; Brenda Simiyu; Taylor Morrisette; Yewande Dayo; Jacinda C Abdul-Mutakabbir
Journal:  Drugs Context       Date:  2022-01-20

5.  Colistin Nephrotoxicity: Meta-Analysis of Randomized Controlled Trials.

Authors:  Khalid Eljaaly; Monique R Bidell; Ronak G Gandhi; Samah Alshehri; Mushira A Enani; Ahmed Al-Jedai; Todd C Lee
Journal:  Open Forum Infect Dis       Date:  2021-01-21       Impact factor: 3.835
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.